Pott, Christiane <br/><br/>
MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.  [electronic resource] 

 -  Leukemia  02 2020 
 - 522-532 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/s41375-019-0559-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bendamustine Hydrochloride--administration & dosage<br/>Female<br/>Humans<br/>Lymphoma, Follicular--drug therapy<br/>Lymphoma, Non-Hodgkin--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm, Residual--drug therapy<br/>Progression-Free Survival<br/>Rituximab--administration & dosage